Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

Prior treatment

• Has donated blood or suffered from blood loss of more than 450 mL (1 unit of blood) within 60 days prior to screening, or donated plasma within 14 days prior to screening.
• Receipt of immunoglobulin, blood-derived products, high dose systemic corticosteroids, or other immunosuppressant drugs within 90 days prior to Day 1 or who expect to receive immunoglobulin or another blood product during the study.
• Receipt of a licensed or emergency/provisional approval vaccine within the last 30 days prior to Day 1.

Other illness

• Chronic illness being treated actively and with evidence of recent adjustments in medications for worsening or fluctuating symptoms in the past 3 months, or hospitalizations / procedural interventions in the past 6 months.
• High risk of contracting HIV.
• History of cancer (malignancy) in the last 10 years.
• Use of narcotic/illicit drugs or a history of drug/alcohol abuse within the past 2 years.
• Known hypersensitivity to any component of the study vaccines, including history of anaphylaxis or other significant allergy in the opinion of the Investigator.
• Any autoimmune or immunodeficiency disease/condition (inherited or iatrogenic) or chronic hematologic disorder (anemia, sickle cell, thalassemia).
• Evidence of HIV, positive hepatitis B surface antigen or core antibody or hepatitis C antibodies by screening test.
• Any chronic or degenerative neurological disease or history of significant neurological disorder.
• Evidence of cardiovascular, pulmonary, renal, hepatobiliary disease or any other baseline condition (history and medication review) that has required active treatment or intervention.
• Evidence of major depression disorder not well controlled in the past 2 years or history of suicidal ideation or attempt in the past 2 years.

Lab values

• Toxicity grading greater than 1 for screening laboratory test results.

Other

• Body mass index (BMI) of less than 17 and greater than 32 kg/m2 at screening.
• Vital signs grading greater than 1 at screening
• Any abnormal, clinically significant ECG result at screening.

• Male or female, 25-55 years of age, inclusive, at screening.
• Stable health status, as established by physical examination and medical history.
• Capable of providing written informed consent.
• Female participants of reproductive potential must be non-pregnant and non lactating, and if of child-bearing potential must agree to be heterosexually inactive from at least 21 days prior to enrolment (Day 1)and through 90 days following last study vaccination or agrees to consistently use highly effective method of birth control and refrain from donating oocytes from at least 21 days prior to enrolment and through 90 days following last study vaccination.
• Male participants must:
  • Agree not to donate sperm from the time of signing consent until at least 90 days after the last dose of study drug.
  • If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception until at least 90 days after the last dose of study drug.
  • If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, must agree to use a condom.